KOSDAQRetail & Consumer299170

WSI

₩1,098▲ 1.39%2026-11-18 close
Market Cap
₩45.6B
Turnover
₩200M
Volume
190K
Shares out.
41.5M
PER
—
PBR
0.8×
EPS
-₩59
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

WSI: Surgical Robot Timing Versus Near-Term Costs

WSI's pharmaceutical and medical device distribution business returned to profit in the second quarter of 2026, but new-business costs and the MFDS approval timing for its U-BOT surgical assist robot remain the largest variables for future earnings.

  1. 1

    Annual revenue rose from KRW 27.1 billion in 2022 to KRW 51.7 billion in 2025, while the operating margin fell from 13.6% to 7.6% over the same period.

  2. 2

    Net income attributable to controlling shareholders turned into a net loss of KRW 3.63 billion in 2025. Operating profit returned to KRW 1.03 billion in the second quarter of 2026 before falling to KRW 255 million in the third quarter.

  3. 3

    Expectations for the MFDS product approval of U-BOT differ, with an independent research firm (Aris) expecting it in the second half of 2026 and Leading Investment & Securities targeting early 2027.

  4. 4

    Because the last four quarters combined show a net loss attributable to controlling shareholders of KRW 1.93 billion, earnings-based multiples cannot be calculated, while the price-to-book ratio sits below 1x.

  5. 5

    The debt-to-equity ratio fell to 38.6% at the end of 2025 from 86.7% in 2024, easing the financial burden.

02

Business structure

WSI, founded in 2016, is a specialized distributor of pharmaceuticals and medical devices. It works with more than 100 medical institutions in Korea and abroad to supply hemostatic agents and surgical disposable devices.

A February 2025 press report said pharmaceuticals were the largest share of revenue at 68%, and hemostatic agents made up 65% of that pharmaceutical revenue.

Since 2024 the company has distributed cardiovascular interventional devices, including central venous catheters and PICCs, through a partnership with UK-based KIMAL PLC.

It acquired a subsidiary developing surgical assist robots in 2022, and in 2024 it took a 67% stake in a pharmaceutical company that owns a drug-formulation technology platform. As of the first half of 2026, the distribution of pharmaceuticals and medical devices accounted for about 63% of total revenue.

Its operating profit is solid, but the R&D burden in medical device manufacturing and development has weighed on overall profitability.

The U-BOT surgical assist robot is positioned as a complementary product used alongside laparoscopic and robotic surgery systems, rather than as a direct competitor to Intuitive Surgical's da Vinci.

The formulation platform is aimed at developing oral versions of peptide injectables such as semaglutide, and the company has started developing generic versions of Novo Nordisk's obesity and diabetes treatment.

In short, the existing distribution business provides steady cash flow, while the new businesses are designed to generate recurring revenue from equipment and dedicated consumables.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩13.4B₩1.1B8.5%
2025Q4₩12.5B₩600M4.9%
2026Q1₩11.9B-₩200M−1.4%
2026Q2₩12.9B₩1B7.9%
2026Q3₩12.5B₩300M2.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩27.1B₩3.7B₩4.3B13.6%11.4%50.9%
2023₩30.9B₩3.3B₩2.8B10.8%7.0%50.1%
2024₩40.4B₩3.9B₩1.3B9.5%3.2%86.7%
2025₩51.7B₩3.9B-₩3.6B7.6%−6.1%38.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

According to DART periodic reports, annual revenue was KRW 27.1 billion in 2022, KRW 30.9 billion in 2023 (up 13.8% year on year), KRW 40.4 billion in 2024 (up 30.9%), and KRW 51.7 billion in 2025 (up 27.9%).

Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025. Operating profit was KRW 3.68 billion in 2022, fell to KRW 3.34 billion in 2023 (down 9.3%), then rose to KRW 3.85 billion in 2024 (up 15.2%) and KRW 3.92 billion in 2025 (up 1.7%).

Operating profit has increased for two consecutive years from 2024 through 2025, and 2023 was the smallest year. Revenue grew, but the operating margin declined every year, from 13.6% in 2022 to 10.8% in 2023, 9.5% in 2024 and 7.6% in 2025, so top-line growth did not translate into better margins.

Net income attributable to controlling shareholders fell from KRW 4.31 billion in 2022 to KRW 2.83 billion in 2023 (down 34.5%) and KRW 1.32 billion in 2024 (down 53.4%). It then turned into a net loss of KRW 3.63 billion in 2025.

Net income including non-controlling interests was a net loss of KRW 3.49 billion in 2025.

In the first half of 2025, the consolidation of Intro Biopharma lifted sales growth, but higher R&D spending and selling and administrative costs from headcount additions reduced profitability, according to a November 2025 brokerage analysis.

Quarterly results show that operating profit was KRW 1.14 billion in the third quarter of 2025, then fell to KRW 610 million in the fourth quarter (down 46.6% from the prior quarter), when net income attributable to controlling shareholders swung to a net loss of KRW 2.68 billion.

In the first quarter of 2026, revenue was KRW 11.9 billion and the company posted an operating loss of KRW 172 million. A press report at the time cited higher R&D and new-business costs as the reason.

In the second quarter of 2026, revenue was KRW 12.9 billion and operating profit returned to KRW 1.03 billion, with net income attributable to controlling shareholders of KRW 851 million.

In the third quarter of 2026, revenue was KRW 12.5 billion (down 6.5% year on year), operating profit was KRW 255 million (down 77.7% year on year), and net loss attributable to controlling shareholders was KRW 190 million.

Across the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, the combined net loss attributable to controlling shareholders was KRW 1.93 billion.

05

Industry analysis

An independent research firm (Aris) analyzed that the surgical robot market in Korea and abroad is growing at an average annual rate of more than 20%.

The global surgical robot market is effectively dominated by Intuitive Surgical's da Vinci, so U-BOT enters as an assistive add-on to existing systems rather than as a direct rival. Aris said this positioning could bring immediate demand from hospitals.

Leading Investment & Securities also viewed the lower need for hospitals to replace equipment as a reason the capital burden is relatively low. Because surgical robots require disposable parts for each procedure, recurring revenue builds as the installed base grows, which brokerages describe as a shared view.

The pace of adoption, however, depends on the approval schedule. On the formulation platform side, an analysis highlighted the shift toward oral obesity treatments, with semaglutide's compound patent expiring after 2028.

In cardiovascular interventional devices, the company has distributed KIMAL PLC products in Korea since 2024 to widen its business. Its existing pharmaceutical distribution is concentrated in hemostatic agents, which leaves product concentration as a weakness in its industry position.

On profitability, the most direct benchmark is the company's own trend, with the operating margin falling from 13.6% in 2022 to 7.6% in 2025.

06

Outlook

The company aims to exceed KRW 100 billion in annual revenue by 2028, nearly double the KRW 51.7 billion recorded in 2025. Aris estimated 2026 consolidated revenue at KRW 55 billion and operating profit at KRW 5 billion.

Compared with the combined first-to-third quarter 2026 results of KRW 37.3 billion in revenue and about KRW 1.11 billion in operating profit, that estimate would require a sharp recovery in the fourth quarter.

For U-BOT, Aris expects product approval and new medical technology certification in the second half of 2026, with meaningful sales from early 2027.

Leading Investment & Securities, by contrast, targets completion of MFDS product approval in early 2027, after producing a final mass-production prototype in the third quarter of 2026.

A September 2026 report also noted that the company is preparing electrical and mechanical safety testing for the domestic product approval.

The company said in September 2026 that a patent covering the uterine lifting robot was registered in 19 European countries, and it has described full-scale exports to Europe and the United States from the second half of 2026.

For 2027, the company plans an automated new factory that would increase production capacity more than threefold versus the existing base, which a February 2025 press report said should gradually improve profitability.

Products based on the formulation platform are targeted for launch after 2028, once semaglutide's compound patent expires. The next checkpoint is therefore the completion of U-BOT's product approval and the timing of its first sales, which would mark when new-business costs begin to translate into profit.

07

Valuation

PER
—
PBR
0.8×
ROE
-3.4%
EPS
-₩59
BPS
₩1,441
Dividend per share
₩0

Because the last four quarters have produced a combined net loss attributable to controlling shareholders, the price-to-earnings ratio cannot be calculated in a meaningful way, and current pricing cannot be described with earnings-based multiples.

Given that earnings measures do not apply, the asset-based measure is the relevant comparison, and the price-to-book ratio sits below 1x. This is a factual comparison showing the market price is below book net asset value, not a judgment on how much the assets are worth.

Dividend yield is effectively negligible, so shareholder returns depend on share price movement. The book reference points at the end of 2025 are KRW 59.6 billion of equity attributable to controlling shareholders and KRW 62.7 billion of total equity.

Total liabilities were KRW 24.2 billion at the end of 2025, which is lower than in 2024. The share price moved sharply on news, including an intraday limit-up move on September 22, 2026, when a patent registration for a subsidiary's robot was announced.

The largest shareholder and related parties held 46.78% as of November 13, 2025, which limits the free float and can amplify price swings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Recurring revenue model if U-BOT launches

U-BOT is structured so that after equipment is supplied to hospitals, dedicated catheters replaced for each procedure generate continuing sales. Leading Investment & Securities analyzed that higher-margin consumables produce recurring revenue as the installed base grows. Aris projected cumulative five-year revenue of KRW 48.6 billion after commercialization in 2027.

Recovery in the existing distribution business

Operating results moved from an operating loss of KRW 172 million in the first quarter of 2026 to operating profit of KRW 1.03 billion in the second quarter. Operating cash flow was KRW 6.74 billion in 2024, the highest among the years reported from 2022 to 2025. The existing pharmaceutical and medical device distribution business accounts for about 63% of total revenue.

Cardiovascular ramp-up and formulation platform

In January 2026, Leading Investment & Securities evaluated that cardiovascular products launched in 2024 would finish ramping up and drive earnings. The same report noted that the formulation platform is being used to develop oral generic semaglutide, with a launch target after 2028. These two factors could support top-line growth separately from the U-BOT approval timeline.

09

Bear factors

Persistent decline in operating margin

The operating margin declined every year, from 13.6% in 2022 to 7.6% in 2025. Net income attributable to controlling shareholders turned into a net loss of KRW 3.63 billion in 2025. Operating profit in the third quarter of 2026 was KRW 255 million, down 77.7% from the same quarter a year earlier.

Diverging approval timelines and costs ahead of revenue

The U-BOT approval timing diverges between Aris's expectation of the second half of 2026 and Leading Investment & Securities's target of early 2027. A September 2026 report described the product as still preparing for electrical and mechanical safety testing for domestic approval. Leading Investment & Securities said profitability improvement in 2026 could be limited by new-business costs.

Financial and governance signals

The debt-to-equity ratio rose to 86.7% in 2024, a period that overlaps with the acquisition of the Intro Biopharma stake. In January 2026, the company's CTO resigned and sold his entire shareholding on the open market, according to disclosure reports.

The combined net loss attributable to controlling shareholders over the last four quarters was KRW 1.93 billion.

10

Risk factors

Approval and commercialization delay

If MFDS approval of U-BOT is delayed, the start of equipment and consumable sales will also slip. A November 2025 brokerage analysis cited approval delays and drug pricing regulation as risk factors. Overseas expansion also requires separate CE and FDA approval processes, which adds to timing risk.

New-business costs and profitability

Higher R&D spending and selling and administrative costs from headcount additions were cited as factors lowering profitability in 2025. The first-quarter 2026 operating loss was also reported to reflect higher R&D and new-business costs. If these costs do not translate into revenue after approval, the pace of margin recovery could slow.

Shareholder structure and share price volatility

The largest shareholder and related parties held 46.78% as of November 13, 2025, which limits the publicly traded float. On September 22, 2026, the share price rose to the daily limit intraday on news of a subsidiary's patent registration, showing sensitivity to news.

Such moves can occur regardless of underlying fundamentals, so share price behavior and business metrics should be considered separately.

11

What to watch next

  1. End of December 2026

    Confirm whether MFDS product approval for U-BOT is granted in line with the second-half 2026 expectation. If not, the timeline would align more closely with Leading Investment & Securities's early 2027 target.

  2. Mid-February 2027

    Preliminary full-year 2026 results are expected around this period. Fourth-quarter revenue and operating profit relative to the first-to-third quarter run rate will show how far results are from the Aris estimate.

  3. March 31, 2027

    This is the filing deadline for the 2026 annual business report. The key checkpoints are whether the operating margin falls below 7.6% from 2025 and how net income attributable to controlling shareholders is finalized.

  4. First half of 2027

    Watch for the domestic launch of U-BOT, initial equipment sales, and the first consumable revenue. A September 2026 report indicated a domestic launch in the first half of 2027, with CE and FDA procedures to follow domestic approval.

  5. 2028

    Check whether annual revenue reaches the KRW 100 billion target and when formulation-platform products launch. The launch is targeted after the expiry of semaglutide's compound patent.

12

Overall view

WSI is a distribution-centered company whose revenue grew from KRW 27.1 billion in 2022 to KRW 51.7 billion in 2025. Over the same period, the operating margin fell from 13.6% to 7.6%, and the company swung to a net loss attributable to controlling shareholders of KRW 3.63 billion in 2025.

After returning to operating profit in the second quarter of 2026, operating profit fell to KRW 255 million in the third quarter, showing that new-business costs and profitability in the existing business are both affecting results.

Strengths include a recurring revenue model for equipment and consumables if U-BOT is approved, a debt-to-equity ratio that fell to 38.6% at the end of 2025, and steady cash flow from distribution.

Weaknesses include diverging approval expectations between the second half of 2026 and early 2027, a combined net loss attributable to controlling shareholders of KRW 1.93 billion over the last four quarters, and new-business costs continuing through 2026.

Because of recent losses, valuation can be described only through asset-based comparisons, with the price-to-book ratio below 1x.

The next checkpoints are the preliminary full-year 2026 results, the operating margin in the 2026 annual business report due by March 31, 2027, and the completion of U-BOT's product approval.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. valueline.co.kr
  4. kbthink.com
  5. sedaily.com
  6. pharm.edaily.co.kr
  7. fnnews.com
  8. pharm.edaily.co.kr
  9. en.edaily.co.kr
  10. markets.hankyung.com
  11. m.news.nate.com
  12. newspim.com
  13. wikitree.co.kr
  14. newspim.com
  15. m.news.nate.com
  16. wsi-healthcare.com
  17. g-enews.com
  18. mt.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis